A topoisomerase II inhibitor that does not cause DNA damage. Induces apoptosis in several cell lines including K562 and Molt-4 cells. Induces a G2 checkpoint that is associated with an ATR-dependent inhibition of polo-like kinase 1 (plk1) activity and a decrease in cyclin B1 phosphorylation.
Product Specification
| Alternative Name: | Meso-4,4'-(3,2-butanediyl)-bis(2,6-piperazinedione) |
| |
| Formula: | C12H18N4O4 |
| |
| MW: | 282.3 |
| |
| CAS: | 21416-68-2 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Appearance: | Off-white to pale yellow solid. |
| |
| Solubility: | Soluble in DMSO (4mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
ATR enforces the topoisomerase II-dependent G2 checkpoint through inhibition of Plk1 kinase: P. B. Deming, et al.; J. Biol. Chem.
277, 36832 (2002),
Abstract;
Full Text
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells: B. B. Hasinoff, et al.; Mol. Pharmacol.
59, 453 (2001),
Abstract;
Full Text
Decreased thymosin beta4 in apoptosis induced by a variety of antitumor drugs: K. Iguchi, et al.; Biochem. Pharmacol.
57, 1105 (1999),
Abstract;
